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Heparin Induced Thrombocytopenia (HIT) 
Heparin is a widely administered for the prevention and treatment of venous and arterial 
thromboembolism. Clinicians who prescribe heparin must be prepared to monitor for potential 
adverse effects; one of the most important of these is an immunoglobulin-mediated reaction, 
heparin induced thrombocytopenia (HIT). 
In this brief review all issues related to “HIT’ could not be addressed, therefore the emphasis 
would be on the important ones.  
 
Clinical Features: HIT (sometimes known as HIT type II, or immune HIT) is characterized by 
thrombocytopenia usually beginning 5-10 days after the start of therapy. Its importance is related 
to its paradoxical high risk of thromboembolic events, like peripheral arterial occlusion, acute MI, 
stroke and death. In addition DVT and pulmonary embolism are strongly associated with HIT. 
Other thrombotic manifestations are adrenal hemorrhagic necrosis leading to hemorrhagic 
infarction, dural sinus thrombosis and venous limb gangrene. 
 
The frequency of HIT is 1-3% in patients receiving unfractioned heparin for 1-2 weeks 
respectively. Typically the platelet count begins to decrease after 5-10 days after starting therapy 
(first day = day zero). It usually decreases by 50% and rarely reaches 10-20 x 10 exp 3/mm. 
Usually  the count does not recover unless heparin is discontinued, after which it returns to 
normal in 4 days in 50% patients and 7 days in 90%, but occasionally requires several weeks for 
recovery. Of interest, bleeding complications are rare despite low platelet count and 
anticoagulation therapy. The disorder can be triggered by any route or dosage of heparin, 
including the flushes administered to maintain patency of IV catheters. 
 
Treatment: Conventionally treatment of HIT requires immediate discontinuation of heparin by any 
route or in any dosage.   
Warfarin: The role is controversial, since this agent is found associated with the unusual 
syndrome of venous limb gangrene in patients with HIT complicated by DVT. 
LMWH: These drugs are considered contraindicated in HIT due to cross-reactivity (with 
unfractioned heparin UFH), high risk of triggering persistent or recurrent thrombocytopenia with 
associated thrombosis, and because other effective treatment options are available. Of interest, it 
should be noted that LMWH are less immunogenic than UFH, it is possible that wider use of 
LMWH in place of UFH will reduce the risk of HIT. 
Treatment Adjuncts: Procedures like limb saving thrombectomy or embolectomy and insertion 
of vena caval filters to prevent pulmonary embolism may be considered. Thrombolytic therapy 
can be effective in selected patients. Aspirin and other antiplatelet agents have a modest 
indication and should not be primary therapy. 
Limited experience suggest that plasma pheresis might work particularly HIT patients with DIC 
(disseminated intravascular coagulation).  
 
 
 
 
 
 
 
 
Newer Treatment Strategies; 
Recombinant Hirudin; Since no structural similarity with heparin, cross-reactivity is not a 
problem. Its effects can be easily monitored by aPTT (target value 1.5-3 times median of normal 
range).  
Argatroban; A selective antithrombin excreted normally in patients with renal failure and may 
therefore be useful in patients with HIT receiving hemodialysis. 
Danaparoid; A safe and effective agent in patients on hemodialysis with an advantage of single 
IV predialysis injection. Safely used in pregnant patient. 
 
Salwa Ahsan (Staff  Pharmacist) 
 
Reference: Pharmacotherpy, vol 19, iss 2 yr 1999      
 
Antibiotics and Dialysis 
 
Antibiotics may be called as life saving agents depending upon the case we are dealing with. 
Many times the course of disease is complicated by renal failure and the need of dialysis. In such 
a scenario in which antibiotics are needed along with dialysis, one has to keep in mind the 
capability of the drug for being dialyzed. For drug, which is removed by dialysis, a supplemental 
doses is needed in order to maintain the therapeutic blood levels. Following list would be help full 
for optimizing dose of commonly used antibiotics in patients undergoing hemodialysis. 
 
Antibiotics    Dialyzable        Supplemental Dose (AD)* 
Ampicillin     Y   500-1000 mg   
**Augmentin     Y   Oral = 375-625 mg 
        IV = 0.6-1.2 gm 
Amikacin     Y   2/3rd of the normal dose 
Aztreonam     Y   500 mg 
Amphotericin B    N   - 
Acyclovir    Y   60-100% of low normal dose 
Cefazolin    Y   2 gm 
Cefixime     N   - 
Ceftazidime     Y   1 gm 
Ceftriaxone     Y   1 gm 
Cefotaxime     Y   1 gm 
Cefepime     Y   Initial dose or 250 mg 
Cephalexin    Y   500 mg 
Ciprofloxacin     Y   250-500 mg 
Co-trimoxazole     Y   50 % of maintenance dose 
Clarithromycin     Y   50 % of maintenance dose 
Fluconazole     Y   100 mg  
Gentamycin    Y   1-1.7 mg/kg 
Levofloxacin     Y   250 mg 
Meropenem     Y   500 mg 
Ofloxacin     Y   100 mg 
Quinine     Y   15 mg/kg Q12 hrly on day of 
dialysis 
Streptomycin     Y   1/2 of normal dose 
**Tazocin     Y   0.75 gm 
Vancomycin     N   - 
             
*After Dialysis  **Brand names (combination product) Y = YES  N = NO 
 
For drugs, which are removed by dialysis, need supplement dose after dialysis in order to 
compensate the lost amount. If dialysis session is near to the dose timing, one can hold the dose 
and give after dialysis; this will save cost of supplemental dose.  
 
Salwa Ahsan (Staff Pharmacist) 
  
         
 
 
Management of Helicobacter pylori Infection 
 
The bacterium Helicobacter pylori can infect the stomach during childhood and cause lifelong 
chronic gastritis, which can lead to peptic ulcer disease. Curing H pylori infection cures ulcer 
disease. And since reinfection in adults is extremely rare, adequate treatment permanently cures 
this former chronic recurrent, serious disease. If ulcers do not recur neither do ulcer perforation or 
bleeding; quality of life increases,  sick leave decreases, and less money is spent on visiting the 
doctor and drugs.  
 
Selecting a regimen: An evidence based choice of treatment is impossible because we lack 
large randomized trials comparing the highly effective regimens. Treatment of H pylori is difficult 
because of the rapid development of resistance to antibiotics, especially to metronidazole, which  
occurs more commonly in women and patients from developing countries because of previous 
treatment for gynecological infections or infective diarrheas. Resistance to clarithromycin may 
occur after failed treatment or after use of this drug for other indications such as respiratory tract 
infections. Dual treatment with proton pump inhibitors is now obsolete due to lack of efficacy. 
Several triple or quadruple therapies have been sufficiently investigated and seem to be able to 
cure either 80% (intention to treat) or 90% (per protocol) of patients. The table shows currently 
useful treatments, but none has surfaced as the final treatment of choice. Metronidazole  and 
clarithromycin are the two key antibiotics. Antibiotic resistance against these two drugs, either 
primary or induced after treatment, is clinically important. 
 
Regimen based on Clarithromycin 
Length of treatment Component Drugs                                                                                             
7-10 days  PPI* bid + Amoxicillin 1 gm twice daily + Clarithromycin 500 mg twice 
daily 
Regimen based on Metronidazole 
Length of treatment Component Drugs                                                                                             
7-10 days  PPI* bid + Amoxicillin 500 mg 2-3 times daily + Metronidazole  400 mg 
twice daily 
 
First Line treatment:   
If metronidazole resistance is likely a proton pump inhibitor in combination with amoxicillin and 
clarithromycin given for one week is preferable. 
 
Second line treatment:  
After a proved failure with a treatment containing metronidazole, a patient is likely to be colonized 
by a resistant strain of H pylori. In this case a proton pump inhibitor should be given in 
combination with amoxicillin and clarithromycin for a week, with about 90% success. If H pylori 
eradication is unsuccessful after a treatment containing clarithromycin and the patient is likely to 
harbour a metronidazole resistant strain of H pylori, then either omeprazole in combination with 
amoxicillin and metronidazole or quadruple therapy (PPI* bid + Colloidal Bismuth Citrate 120 mg 
qid + Tetracycline 500 mg Q6H + Metronidazole 400 mg Q6H) are the only logical options, with 
roughly 75% success. The regimens containing clarithromycin plus metronidazole should be 
disfavored as in case of treatment failure the back up plan options will be limited. 
 
What to tell patients? There has been much discussion of H pylori in the media, and many 
patients are aware of its ulcerogenic and carcinogenic potential and may request antibacterial 
treatment if they are found to be infected. At present there is no evidence to suggest that 
screening and treating patients without risk factors will prevent gastric cancer. The risk of 
transmission to partners is low in adults, and treatment of the entire family is not warranted. 
Whatever treatment is chosen, patients need careful counseling. The reasons for embarking on 
the treatment and the importance of compliance despite possible side effects need to be 
emphasized, and the possible side effects must be carefully discussed. The need for good 
compliance needs special attention, as it is crucial to the success of treatment. 
 
*PPI = Proton Pump Inhibitor (Omeprazole 20 mg bid) 
 
Abdul Qadeer Sajid (Pharmacist) 
 
References: BMJ vol. 323, Nov 2001. BMJ, vol 320, Jan 2000 
 
 
 
Story of A Pharmacist In a Busy Pharmacy  
 
A pharmacist, who was working alone in a busy hospital pharmacy, received a stat order for oral 
clonidine 1 mg and levodopa 125 mg for a growth hormone stimulation test on an 8year-old child.  
 
Despite significant pressure from the stat order and a backlog of work, the pharmacist, who was 
unfamiliar with the test, took time to research the information and discovered that the correct test 
dose of clonidine for a pediatric patient was 0.15 mg/meter square.  
 
After calling the physician, the order was changed to clonidine 0.1 mg. Unfortunately, even 
successful outcomes like this one may not be widely appreciated if productivity is sacrificed to 
enhance patient safety. Nevertheless, numerous errors reported through the USP-ISMP 
Medication Errors Reporting Program have resulted when practitioners felt significant pressure to 
place productivity above patient safety, especially when faced with inadequate staffing. Institute 
for Safe Medication Practices (ISMP). 
Heparin is a widely administered for the prevention and treatment of venous and arterial 
thromboembolism. Clinicians who prescribe heparin must be prepared to monitor for potential 
adverse effects; one of the most important of these is an immunoglobulin-mediated reaction, 
heparin induced thrombocytopenia (HIT). 
In this brief review all issues related to “HIT’ could not be addressed, therefore the emphasis 
would be on the important ones.  
 
ACE inhibitor, diuretic and NSAID: a dangerous combination 
The control of hypertension by ACE inhibitors and diuretics and their beneficial effects in heart 
failure are antagonised by NSAIDs. Concurrent use of NSAIDs and diuretics is associated with a 
twofold increase in the risk of hospitalisation for heart failure compared with diuretics alone.1 
Moreover, ACE inhibitors, NSAIDs and diuretics, individually or in combination, are involved in 
over 50% of cases of iatrogenic acute renal failure reported. 
More specifically, the combined use of ACE inhibitors, diuretics and NSAIDs, termed the "triple 
whammy", is implicated in a significant number of reports of drug-induced renal failure.2 This 
effect is also seen with COX-2 inhibitors and angiotensin receptor antagonists ("sartans").3 In 
2002, 28 of the 129 reports of acute renal failure implicated one of these combinations. Most 
reports of drug-induced renal failure relate to elderly patients, and this applies as well to renal 
failure associated with the triple therapy (median age 76 years). The fatality rate for cases of 
renal failure with the "triple whammy" is 10%. 
The use of ACE inhibitors and angiotensin receptor antagonists is increasing, as is the use of 
these agents in combination products with a diuretic. Episodes of renal failure appear to be 
precipitated by mild stress (e.g. diarrhoea, dehydration) in a patient taking the triple combination 
or by the addition of a third drug (usually an NSAID) to the stable use of the other two.  
It is therefore to remind prescribers that the combination of ACE inhibitors (or angiotensin 
receptor antagonists), diuretics and NSAIDs (including COX-2 inhibitors) should be avoided if 
possible, and great care should be taken with ACE inhibitors and NSAIDs in patients with renal 
impairment. 
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